Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke

doi:10.1038/modpathol.2017.46

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Alessandro Lugli^*, Richard Kirsch, Yoichi Ajioka, Fred Bosman, Gieri Cathomas, Heather Dawson, Hala El Zimaity, Jean François Fléjou, Tine Plato Hansen, Arndt Hartmann, Sanjay Kakar, Cord Langner, Iris Nagtegaal, Giacomo Puppa, Robert Riddell, Ari Ristimäki, Kieran Sheahan, Thomas Smyrk, Kenichi Sugihara, Benoît TerrisHideki Ueno, Michael Vieth, Inti Zlobec, Phil Quirke

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

283 Citationer (Scopus)

Abstract

Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: Tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm 2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.

Originalsprog	Engelsk
Tidsskrift	Modern Pathology
Vol/bind	30
Sider (fra-til)	1299-1311
Antal sider	13
ISSN	0893-3952
DOI	https://doi.org/10.1038/modpathol.2017.46
Status	Udgivet - 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/modpathol.2017.46

modpathol201746.pdfForlagets udgivne version, 4,18 MB

Citationsformater

Lugli, A., Kirsch, R., Ajioka, Y., Bosman, F., Cathomas, G., Dawson, H., El Zimaity, H., Fléjou, J. F., Hansen, T. P., Hartmann, A., Kakar, S., Langner, C., Nagtegaal, I., Puppa, G., Riddell, R., Ristimäki, A., Sheahan, K., Smyrk, T., Sugihara, K., ... Quirke, P. (2017). Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology, 30, 1299-1311. https://doi.org/10.1038/modpathol.2017.46

Lugli, A, Kirsch, R, Ajioka, Y, Bosman, F, Cathomas, G, Dawson, H, El Zimaity, H, Fléjou, JF, Hansen, TP, Hartmann, A, Kakar, S, Langner, C, Nagtegaal, I, Puppa, G, Riddell, R, Ristimäki, A, Sheahan, K, Smyrk, T, Sugihara, K, Terris, B, Ueno, H, Vieth, M, Zlobec, I & Quirke, P 2017, 'Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016', Modern Pathology, bind 30, s. 1299-1311. https://doi.org/10.1038/modpathol.2017.46

@inproceedings{4ef23b1abfd0466aa0d879e287e88796,

title = "Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016",

abstract = "Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: Tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm 2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.",

author = "Alessandro Lugli and Richard Kirsch and Yoichi Ajioka and Fred Bosman and Gieri Cathomas and Heather Dawson and {El Zimaity}, Hala and Fl{\'e}jou, {Jean Fran{\c c}ois} and Hansen, {Tine Plato} and Arndt Hartmann and Sanjay Kakar and Cord Langner and Iris Nagtegaal and Giacomo Puppa and Robert Riddell and Ari Ristim{\"a}ki and Kieran Sheahan and Thomas Smyrk and Kenichi Sugihara and Beno{\^i}t Terris and Hideki Ueno and Michael Vieth and Inti Zlobec and Phil Quirke",

year = "2017",

doi = "10.1038/modpathol.2017.46",

language = "English",

volume = "30",

pages = "1299--1311",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "nature publishing group",

}

TY - GEN

T1 - Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

AU - Lugli, Alessandro

AU - Kirsch, Richard

AU - Ajioka, Yoichi

AU - Bosman, Fred

AU - Cathomas, Gieri

AU - Dawson, Heather

AU - El Zimaity, Hala

AU - Fléjou, Jean François

AU - Hansen, Tine Plato

AU - Hartmann, Arndt

AU - Kakar, Sanjay

AU - Langner, Cord

AU - Nagtegaal, Iris

AU - Puppa, Giacomo

AU - Riddell, Robert

AU - Ristimäki, Ari

AU - Sheahan, Kieran

AU - Smyrk, Thomas

AU - Sugihara, Kenichi

AU - Terris, Benoît

AU - Ueno, Hideki

AU - Vieth, Michael

AU - Zlobec, Inti

AU - Quirke, Phil

PY - 2017

Y1 - 2017

N2 - Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: Tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm 2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.

AB - Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: Tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm 2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.

U2 - 10.1038/modpathol.2017.46

DO - 10.1038/modpathol.2017.46

M3 - Conference article

C2 - 28548122

AN - SCOPUS:85028709487

SN - 0893-3952

VL - 30

SP - 1299

EP - 1311

JO - Modern Pathology

JF - Modern Pathology

ER -

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater